RLMD - RELMADA THERAPEUTICS, INC.

0.2601
-0.012   -4.729%

Share volume: 433,245
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$0.27
-0.01
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 8%
Dept financing 4%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.73%
1 Month
-4.38%
3 Months
-42.46%
6 Months
-92.55%
1 Year
-94.65%
2 Year
-88.59%
Key data
Stock price
$0.26
P/E Ratio 
0.00
DAY RANGE
$0.25 - $0.28
EPS 
-$2.66
52 WEEK RANGE
$0.24 - $4.90
52 WEEK CHANGE
-$94.58
MARKET CAP 
15.685 M
YIELD 
N/A
SHARES OUTSTANDING 
30.174 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
2.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$356,930
AVERAGE 30 VOLUME 
$385,362
Company detail
CEO: Sergio Traversa
Region: US
Website: relmada.com
Employees: 10
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Relmada Therapeutics, Inc. focuses on developing various products for the treatment of central nervous system diseases and other disorders. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Its lead product candidate is Esmethadone, a new chemical entity and N-methyl-D-aspartate receptor antagonist.

Recent news
loading